hit counter
Cancer Genetics, Inc. (CGIX) Stock News Sentiment & Price - Sentifly
CGIX - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Cancer Genetics, Inc. (CGIX)

USA
Medical Laboratories & Research
NASDAQ
CGIX Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
CGIX Latest news
GlobeNewsWire
Neutral
Cancer Genetics and StemoniX Announce Merger Closing
2021-03-31 06:30

Cancer Genetics, Inc. Renamed to Vyant Bio, Inc.

GlobeNewsWire
Neutral
Cancer Genetics Announces Shareholder Approval of All Proposals in Connection with the Proposed Merger with StemoniX
2021-03-25 09:15

Combined entity creates an innovative platform to de-risk and accelerate the discovery and development of preclinical and clinical pipelines with biopharma partners as well as the proprietary pipeline of the combined company

GlobeNewsWire
Neutral
Cancer Genetics to Present at the Annual 33rd ROTH Conference
2021-03-12 09:30

RUTHERFORD, N.J., March 12, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts, Chief Executive Officer, will present at the Annual 33rd ROTH Conference. The event is being held virtually from March 15-17, 2021.

GlobeNewsWire
Neutral
Cancer Genetics to Present at the H.C. Wainwright Global Life Sciences Conference
2021-03-04 16:15

RUTHERFORD, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), an emerging leader in novel drug discovery techniques, announced today that Jay Roberts, Chief Executive Officer, will present at H.C. Wainwright's Global Life Sciences Conference. The event is being held virtually from March 9-10, 2021.

GlobeNewsWire
Neutral
Cancer Genetics Announces Closing of $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules
2021-02-16 16:45

RUTHERFORD, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced the closing of its previously announced registered direct offering with several healthcare-focused institutional investors of 2,777,778 shares of its common stock at a purchase price of $6.30 per share, priced at-the-market under Nasdaq rules. The gross proceeds to the Company from the offering totaled approximately $17.5 million, before deducting placement agent fees and offering expenses.

GlobeNewsWire
Neutral
Cancer Genetics Announces $17.5 Million Common Stock Offering Priced At-the-Market under Nasdaq Rules
2021-02-10 23:00

RUTHERFORD, N.J., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced that it has entered into securities purchase agreements with certain healthcare-focused institutional investors to raise approximately $17.5 million through the issuance of 2,777,778 shares of its common stock at a purchase price of $6.30 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about February 16, 2021, subject to the satisfaction of customary closing conditions.

Benzinga
Positive
Why AzurRx BioPharma, Usana Health Are Moving Today
2021-02-10 11:47

Usana Health Sciences (NYSE: USNA) shares are trading higher after the company reported better-than-expected Q4 EPS and sales results and issued fiscal year 2021 EPS and sales guidance above estimates. The company also announced a $150 million buyback.

InvestorPlace
Positive
CGIX Stock: Why Cancer Genetics Shares Are Rocketing Higher Today
2021-02-10 08:20

Cancer Genetics said its board has approved the StemoniX merger, setting the stage for a March shareholder vote. In the wake of the move, investors drove up the CGIX stock price in Wednesday's premarket trading.

Pulse2
Positive
CGIX Stock Price Increases Over 240% Pre-Market: Why It Happened
2021-02-10 06:01

The stock price of Cancer Genetics Inc (NASDAQ: CGIX) is trading at over 240% pre-market as of 5:45 AM ET. This is why it happened.

GlobeNewsWire
Neutral
Cancer Genetics Announces Closing of $10.0 Million Private Placement Priced At-the-Market
2021-02-01 17:16

RUTHERFORD, N.J., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (the “Company”) (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced the closing of its previously announced private placement of approximately $10.0 million through the issuance of an aggregate 2,758,624 shares of its common stock and warrants to purchase up to an aggregate 2,758,624 shares of common stock, at a combined purchase price of $3.625 per share of common stock and associated warrant in a private placement priced at-the-market under Nasdaq rules.

Loading more news...